HK Stock Market Move | Dongfeng Group (00489) rose more than 17% in the afternoon, market value management guidelines introduced, company's price-to-book ratio is only 0.17.
Dongfeng Group's stock (00489) increased by more than 17% in the afternoon, reaching a gain of 13.38% at 3.39 Hong Kong dollars per share with a trading volume of 479 million Hong Kong dollars at the time of publication.
DONGFENG GROUP (00489) rose more than 17% in the afternoon, up 13.38% to HK$3.39 billion with a turnover of HK$4.79 billion.
On the news front, the China Securities Regulatory Commission officially released the "14 Measures for Market Value Management," requiring listed companies to improve their market value management level and protect the interests of investors. It specifically requires main index component stocks and long-term companies with low market-to-book ratios to formulate plans to increase their valuations. It is worth noting that DONGFENG GROUP currently has a price-to-book ratio of only 0.171.
China Securities Co., Ltd. pointed out that the release and implementation of the market value management guidelines will have a positive impact on listed companies in the construction and decoration industry with long-term low market-to-book ratios. The release of the market value management guidelines will guide companies to enhance their own value through methods such as increasing holdings, buybacks, capital operations, dividends, etc., and return the valuation to 1XPB.
Related Articles

MENGNIU DAIRY (02319) spent HK$3.0429 million on repurchasing 200,000 shares on September 18th.

China International Marine Containers (02039) spent 9.8927 million Hong Kong dollars on repurchasing 1.2472 million shares on September 18th.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials
MENGNIU DAIRY (02319) spent HK$3.0429 million on repurchasing 200,000 shares on September 18th.

China International Marine Containers (02039) spent 9.8927 million Hong Kong dollars on repurchasing 1.2472 million shares on September 18th.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials
